Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
Greer YE, Hernandez L, Fennell EMJ, Kundu M, Voeller D, Chari R, Gilbert SF, Gilbert TSK, Ratnayake S, Tang B, Hafner M, Chen Q, Meerzaman D, Iwanowicz E, Annunziata CM, Graves LM, Lipkowitz S. Greer YE, et al. Cancer Res Commun. 2022 Oct 10;2(10):1144-1161. doi: 10.1158/2767-9764.CRC-22-0142. Cancer Res Commun. 2022. PMID: 36388465 Free PMC article.
TIC10/ONC201: a bend in the road to clinical development.
Greer YE, Lipkowitz S. Greer YE, et al. Oncoscience. 2015 Feb 20;2(2):75-6. doi: 10.18632/oncoscience.133. eCollection 2015. Oncoscience. 2015. PMID: 25859547 Free PMC article. No abstract available.
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. Dine JL, et al. Among authors: greer ye. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12. Breast Cancer Res Treat. 2016. PMID: 26759246 Free PMC article.
ONC201 kills breast cancer cells in vitro by targeting mitochondria.
Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S. Greer YE, et al. Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6. Oncotarget. 2018. PMID: 29719618 Free PMC article.
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S. Greer YE, et al. Breast Cancer Res. 2019 Feb 18;21(1):27. doi: 10.1186/s13058-019-1116-1. Breast Cancer Res. 2019. PMID: 30777098 Free PMC article.
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
Fennell EMJ, Aponte-Collazo LJ, Wynn JD, Drizyte-Miller K, Leung E, Greer YE, Graves PR, Iwanowicz AA, Ashamalla H, Holmuhamedov E, Lang H, Karanewsky DS, Der CJ, Houry WA, Lipkowitz S, Iwanowicz EJ, Graves LM. Fennell EMJ, et al. Among authors: greer ye. Pharmacol Res Perspect. 2022 Aug;10(4):e00993. doi: 10.1002/prp2.993. Pharmacol Res Perspect. 2022. PMID: 35929764 Free PMC article.
21 results